Description
Pramlintide is a synthetic polypeptide analog of human amylin, engineered with three proline substitutions to reduce amyloid formation and improve stability. Co-secreted with insulin from pancreatic ?-cells, amylin complements insulin’s glucose-regulating actions. Pramlintide slows gastric emptying, suppresses postprandial glucagon secretion, and promotes a feeling of fullness—collectively helping to moderate post-meal blood glucose spikes. Clinically approved as an adjunct to mealtime insulin for both type 1 and type 2 diabetes, pramlintide effectively reduces HbA1c, body weight, and insulin dosage. With ?99.94% purity and manufactured to GMP standards, this peptide is ideal for metabolic and endocrinology research focusing on satiety, glucose dynamics, and hormone regulation.
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | Pramlintide |
| CAS Number | 151126-32-8 |
| Purity | ?99.94% (HPLC) |
| Structure | Human amylin analog with proline substitutions |
| Function | Amylin receptor agonist (modulates glucose regulation postprandially) |
| Therapeutic Usage | Adjunct to insulin therapy in diabetes |
| Appearance | White to off-white lyophilized powder |
| Form | TFA salt |
| Solubility | Soluble in aqueous solutions; standard peptide handling protocols apply |
| Storage | –20 °C, protected from light and moisture |
| GMP Compliance | Yes – manufactured in GMP-certified facility |
Mechanism of Action & Research Applications
Pramlintide acts through multiple mechanisms to support metabolic balance:
Slows gastric emptying, delaying nutrient uptake and reducing the rate of glucose absorption
Suppresses inappropriate post-meal glucagon secretion, lowering hepatic glucose output
Promotes satiety, helping to reduce caloric intake and facilitating weight control
These combined effects not only improve postprandial glycemic control but also aid in managing body weight via appetite regulation. Pramlintide serves as an excellent research model for exploring satiety signaling, incretin-like effects, insulin/amylin synergy, and metabolic control dynamics.
Side Effects (For Research Context Only)
In clinical settings, common adverse effects include nausea, vomiting, anorexia, headache, dizziness, and injection site discomfort. Severe hypoglycemia may occur if mealtime insulin is not adjusted appropriately—usually mitigated by reducing insulin doses upon pramlintide initiation.
For experimental protocols, careful titration and glucose monitoring are essential to preserve safety and data integrity.
Logistics Transportation
All shipments come with full transport insurance and expedited handling. In the rare event of loss, damage, or detention, 100% compensation is guaranteed—ensuring secure and reliable delivery.
Disclaimer
This product is intended strictly for laboratory research use only. It is not approved for clinical, therapeutic, veterinary, or diagnostic applications.


Reviews
There are no reviews yet.